Imerys published Q3 results above the market expectations due to better-than-expected pricing and well-delivered cost control. The company remains uncertain about the market recovery at present but did confirm that it will be able to achieve the lower end of its EBITDA guidance (in-line with our estimate) considering its ability to keep yoy prices flat or just slightly negative and through active cost management.